Jitka Palich FuÄÃ-kovÃ¡

List of Publications by Year
in descending order

57 papers	6,540 citations	136950 32 h-index	182427 51 g-index
58 all docs	58 docs citations	58 times ranked	8650 citing authors

#	Article	IF	Citations
1	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
2	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
3	Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death and Disease, 2020, 11, 1013.	6.3	466
4	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
5	Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response. Cancer Research, 2011, 71, 4821-4833.	0.9	355
6	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	4.8	317
7	Combinatorial Strategies for the Induction of Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 187.	4.8	289
8	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology, 2015, 4, e1008866.	4.6	237
9	Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. OncoImmunology, 2015, 4, e965570.	4.6	189
10	Calreticulin and cancer. Cell Research, 2021, 31, 5-16.	12.0	174
11	Calreticulin Expression in Human Nonâ€“Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. Cancer Research, 2016, 76, 1746-1756.	0.9	164
12	Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. OncoImmunology, 2014, 3, e968434.	4.6	160
13	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449.	4.6	156
14	High hydrostatic pressure induces immunogenic cell death in human tumor cells. International Journal of Cancer, 2014, 135, 1165-1177.	5.1	151
15	Trial watch. OncoImmunology, 2013, 2, e25771.	4.6	150
16	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Frontiers in Immunology, 2015, 6, 402.	4.8	135
17	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
18	Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget, 2015, 6, 18192-18205.	1.8	111

#	Article	IF	Citations
19	Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 2016, 128, 3113-3124.	1.4	107
20	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. OncoImmunology, 2016, 5, e1088631.	4.6	104
21	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814.	4.6	102
22	Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications. Frontiers in Immunology, 2019, 10, 2393.	4.8	92
23	Dynamics of Tâ€cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory Tâ€cells. International Journal of Cancer, 2013, 132, 1070-1079.	5.1	89
24	Trial Watchâ€"Oncolytic viruses and cancer therapy. OncoImmunology, 2016, 5, e1117740.	4.6	88
25	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 4820-4831.	7.0	71
26	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	12.8	71
27	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	4.6	64
28	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	4.6	62
29	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. , 2020, 8, e000979.		60
30	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, .	4.6	54
31	Trial Watchâ€"Immunostimulation with cytokines in cancer therapy. OncoImmunology, 2016, 5, e1115942.	4.6	52
32	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. , 2019, 7, 312.		52
33	Trial Watchâ€"Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology, 2016, 5, e1149674.	4.6	46
34	Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. Journal of Translational Medicine, 2011, 9, 223.	4.4	38
35	FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clinical Immunology, 2009, 131, 1-10.	3.2	36
36	Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. Cancer Immunology, Immunotherapy, 2018, 67, 89-100.	4.2	36

#	Article	IF	Citations
37	Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer. Immunology Letters, 2018, 193, 25-34.	2.5	36
38	Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. OncoImmunology, 2020, 9, 1830524.	4.6	34
39	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. International Journal of Oncology, 2016, 48, 953-964.	3.3	33
40	Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica, 2020, 105, 1868-1878.	3.5	32
41	Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. OncoImmunology, 2017, 6, e1258505.	4.6	30
42	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. OncoImmunology, 2021, 10, 1962592.	4.6	30
43	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30
44	Trial Watch: Adoptive cell transfer for oncological indications. OncoImmunology, 2015, 4, e1046673.	4.6	29
45	Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology, 2015, 4, e1026531.	4.6	26
46	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clinical Cancer Research, 2022, 28, 3053-3065.	7.0	26
47	TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. OncoImmunology, 2021, 10, 1889822.	4.6	21
48	Calreticulin arms NK cells against leukemia. OncoImmunology, 2020, 9, 1671763.	4.6	16
49	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. , 2022, 10, e003190.		16
50	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice. OncoImmunology, 2017, 6, e1362528.	4.6	15
51	RNA-seq of macrophages of amoeboid or mesenchymal migratory phenotype due to specific structure of environment. Scientific Data, 2018, 5, 180198.	5.3	13
52	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer, 2022, 8, 426-444.	7.4	13
53	Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling. Journal of Controlled Release, 2021, 332, 563-580.	9.9	11
54	Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs. Immunology Letters, 2014, 160, 39-49.	2.5	8

#	Article	IF	Citations
55	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. Methods in Enzymology, 2020, 632, 15-25.	1.0	3
56	Methods to assess DC-dependent priming of T cell responses by dying cells. Methods in Enzymology, 2020, 632, 55-65.	1.0	1
57	Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood. Methods in Enzymology, 2020, 631, 277-287.	1.0	0